Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DNA vs STEM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DNA Captures Overall Composite Edge (52.1 HOLD vs 42.4 HOLD), While STEM Leads 4–2 on Growth & Valuation Pillars

DNA Overall Winner 6-Pillar Tally: DNA 2 – 4 STEM Matrix Metrics: DNA 5 – 3 STEM

As of Nov 20, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) captures the overall head-to-head institutional edge over Stem, Inc. (STEM) on higher Unified Composite conviction (52.1/100 HOLD vs. 42.4/100 HOLD) after splitting the core matrix 5–3 (led by Valuation Multiples, Options & Positioning), while STEM wins 4–2 across the 6-pillar growth and valuation breakdown. DNA trades at $7.46 (N/M Forward P/E, -202.5% operating margin) versus STEM at $0.64 (N/M Forward P/E, -12.1% operating margin).

  • Growth vs. Quality Trade-Off: DNA earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. STEM 42.4/100 HOLD) and 3.12β · 152% Vol risk profile, whereas STEM leads top-line expansion (-4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DNA is currently in a Breakdown options structure phase (RSI 37.0); meanwhile STEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DNA vs STEM
DNA NYSE Head-to-Head Winner
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$7.46
-9.02% 1D
Market Cap $531.5M
TTM Revenue $131M
Forward P/E N/M
Beta / 30D Vol 3.12β · 152% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.0 · SMA20: $10.37 · SMA50: $10.42
STEM NYSE
Stem, Inc.
Miscellaneous Electrical Machinery, Equipment & Supplies
$0.64
-12.73% 1D
Market Cap $7.1M
TTM Revenue $146M
Forward P/E N/M
Beta / 30D Vol 4.60β · 234% Vol
Unified Composite Score
42.4 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 61.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.5%), weak momentum, RSI 23
RSI-14: 22.9 · SMA20: $2.13 · SMA50: $3.30

6-Pillar Scorecard Institutional Category Breakdown (DNA 2 – 4 STEM)

Columns: Metric · DNA · STEM
1. Valuation Multiples DNA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.5x N/M
2. Growth & Scale STEM
Revenue Growth (YoY) -5.7% -4.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $131M $146M
Market Cap $531.5M $7.1M
3. Profitability & Quality STEM
Gross Margin 69.8% 47.6%
Operating Margin -202.5% -12.1%
Net Profit Margin -192.0% -43.6%
Return on Equity (ROE) -58.2% -5920.8%
4. Balance Sheet & Cash Flow STEM
Cash Generation (TTM) -$174M $7.1M
Cash Flow Margin N/A 4.9%
Net Cash / Leverage $313M Net Debt (1.01x D/E) -5920.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DNA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.7% (22nd %ile) 175.8% (39th %ile)
Put/Call OI Skew 0.78x (Call-Skewed) 0.14x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat STEM
OpEx & R&D Intensity N/A 59.7% of Rev ($87M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Utilities - Renewable Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DNA (5) vs STEM (3)
Institutional Metric DNA STEM Criterion Row Edge
Market Capitalization
Scale
$531.5M $7.1M Larger Scale DNA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-5.7% -4.1% Higher Growth STEM
Operating Margin (TTM)
Profitability
-202.5% -12.1% Higher Margin STEM
Net Profit Margin
Profitability
-192.0% -43.6% Higher Margin STEM
Return on Equity (ROE)
Capital Efficiency
-58.2% -5920.8% Higher ROE DNA
52-Week Range Position
Momentum
16% ($5–$18) 0% ($1–$22) Stronger Trend DNA
Beta / 30D Volatility
Risk Regime
3.12β · 152% Vol 4.60β · 234% Vol Lower Realized Risk DNA
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 42.4 / 100 (HOLD) Higher Composite DNA
Trailing 12M Revenue (USD)
Operating Scale
$131M $146M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
69.8% 47.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$174M ($313M Net Debt (1.01x D/E)) $7.1M (-5920.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DNA +55.6 pp
DNA: -23.17% · STEM: -78.77%
3M Horizon DNA +98.29 pp
DNA: +10.03% · STEM: -88.26%
6M Horizon DNA +81.92 pp
DNA: -11.3% · STEM: -93.22%
1Y Horizon DNA +90.15 pp
DNA: -5.69% · STEM: -95.84%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DNA Revenue STEM Revenue DNA Op. Margin STEM Op. Margin Margin Leader
FY2019 $50M $20M -132.1% -272.6% DNA
FY2020 $80M $40M -178.8% -136.0% STEM
FY2021 $310M $130M -582.6% -65.2% STEM
FY2022 $480M $360M -462.4% -36.1% STEM
FY2023 $250M $460M -343.8% -38.9% STEM
FY2024 $230M $140M -246.5% -580.6% DNA
FY2025 $170M $160M -185.3% -35.6% STEM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DNA BREAKDOWN
34d in phase · OBV DISTRIBUTION
Current IV 101.7%
IV Percentile 22nd %ile
Put/Call OI Skew 0.78x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact DNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STEM BREAKDOWN
145d in phase · OBV DISTRIBUTION
Current IV 175.8%
IV Percentile 39th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact STEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $7.65 · IV 104.2%

DNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($765)

Compare $765 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 104.2% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $7 / $6 Bull Put Spread

Sell 4x $7P · Buy 4x $6P · 28d

Net Entry $92 Credit
Max Credit / Yield +$92 (+29.9% RoM)
Max Risk / Buffer -11.5% Cushion ($308 Mgn)
5d Edge & Liquidity 69% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $8 / $7 Bear Put Spread

Buy 3x $8P · Sell 3x $7P · 28d

Net Entry $180 Debit
T+5d @ -5% Drop +$22 (+12%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.6x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $531.5M market capitalization and -202.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STEM Moat Profile Cyclical / Execution-Driven Positioning
Utilities - Renewable Operator
Competes within the Utilities - Renewable value chain with $7.1M market capitalization and -12.1% operating margin.
OpEx & R&D Reinvestment 59.7% of Rev ($87M)
90D Engineering Disclosures 0 Published

Investor FAQ DNA vs STEM Key Questions & Quantitative Answers

As of Nov 20, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) captures the overall head-to-head institutional edge over Stem, Inc. (STEM) on higher Unified Composite conviction (52.1/100 HOLD vs. 42.4/100 HOLD) after splitting the core matrix 5–3 (led by Valuation Multiples, Options & Positioning), while STEM wins 4–2 across the 6-pillar growth and valuation breakdown. DNA trades at $7.46 (N/M Forward P/E, -202.5% operating margin) versus STEM at $0.64 (N/M Forward P/E, -12.1% operating margin). Growth vs. Quality Trade-Off: DNA earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. STEM 42.4/100 HOLD) and 3.12β · 152% Vol risk profile, whereas STEM leads top-line expansion (-4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DNA is currently in a Breakdown options structure phase (RSI 37.0); meanwhile STEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STEM leads the Growth & Scale pillar: DNA posts -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin), compared with STEM at -4.1% YoY revenue growth and +0.0% YoY earnings growth on $146M TTM revenue (47.6% gross margin, -12.1% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), DNA cumulative revenue shifted +240.0% while STEM shifted +700.0%. In operating R&D and SG&A reinvestment, DNA deploys N/A (0 90-day corporate R&D disclosures) versus 59.7% of Rev ($87M) (0 disclosures) for STEM.

DNA screens cheaper on headline valuation multiples. DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.5x EV/Revenue (unreported FCF margin), whereas STEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (4.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DNA (-58.2% ROE) versus STEM (-5920.8% ROE) capital efficiency.

In options market volatility and institutional positioning, DNA carries 101.7% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.78x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.12β · 152% Vol realized risk). By comparison, STEM carries 175.8% implied volatility (39th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (4.60β · 234% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.